<![CDATA[Overall Survival With Amivantamab Plus Lazertinib in MARIPOSA]]>

Phase 3positiveamivantamablazertinibPositive

AI Analysis

Summary

Mature overall survival data from the phase 3 MARIPOSA study of amivantamab plus lazertinib in EGFR-mutated advanced non-small cell lung cancer was presented, demonstrating positive efficacy results with the combination therapy.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Mature overall survival data from MARIPOSA phase 3 study

Importance:7/10

Sentiment:

0.70

oncologylung cancerNSCLCEGFR mutationcombination therapyoverall survival

Related Companies

$CMHSF

Read the original article

Published by Cancer Network on September 21, 2026 12:05 PM

Read Original